Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study

Fig. 1

Kaplan-Meier survival curves illustrating progression-free survival (PFS). A Patients receiving chemotherapy plus immune checkpoint inhibitors (ICI), stratified by baseline C-reactive protein (CRP) levels (elevated vs. normal). B Patients receiving chemotherapy alone, stratified by baseline CRP levels (elevated vs. normal). The ‘+’ symbols represent censored data points, indicating times at which patients were lost to follow-up without experiencing the event of interest. The log-rank test was used to compare the survival distributions, and the difference was found to be statistically significant (p < 0.05)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us